- Celtic Pharma Announces Update on Status of XERECEPT® Program Sale Planned in 2009
- Celtic Pharmaceutical Holdings and Inspiration Biopharmaceuticals Forge Collaboration To Deliver Improved Therapies to Patients with Hemophilia B
2007
- Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on XERECEPT® Clinical Program
- Celtic Pharma completes rapid enrollment in Phase IIB study for TA-NIC, the nicotine vaccine for smoking cessation
- Celtic Pharma Announces Initiation of Phase II Clinical Trial for TDT-067, a Treatment for Onychomycosis
- Celtic Pharma portfolio company, IDEA AG, signs major licensing agreement with Alpharma Inc.
- Celtic Pharma and Neurobiological Technologies report updated results from long-term open-label extension study for Xerecept, and its clinical development status
- Celtic Pharma receives IND approval to initiate a large randomized study in the US for TA-NIC, its immunotherapy vaccine for the treatment of smoking cessation.
- Celtic Pharmaceutical Holdings L.P. Raises $156 Million in Debt, Bringing Total Capital to over $400 Million
- Celtic Pharma Terminates Transmid™ Trial Ksb311R/Ciii/001
2006
- Celtic Pharma appoints two new senior executives
- XERECEPT® Update Presented at Society for Neuro-Oncology Meeting
- Celtic Pharma Notes Progress By IDEA AG
- Celtic Pharma Reports Preliminary Results Of Phase 2 Clinical Trials With TA-CD, Cocaine Addiction Vaccine
- Michael Earl joins
- Reinaldo Diaz joins
- Fulcrum Pharma alliance signed
- IDEA AG license acquired
- XERECEPT® 2nd Phase III trial started
2005
Celtic Pharma Announces Completion of Enrollment in Dose Tolerance Trial Evaluating XERECEPT® in Pediatric Patients with Primary and Metastatic Brain Tumors
October 03, 2011
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”) is pleased to announce the completion of enrollment into a maximum dose tolerance study of investigational product Xerecept® (corticorelin acetate) in pediatric patients who were dependent on chronic Decadron (dexamethasone) dosing due to peritumoral brain edema associated with cerebral tumors. In the open label study, 100% of the subjects showed substantive reductions in daily dexamethasone dosing requirements, with approximately 25% of patients able to completely stop steroid dosing.
Read the full press release
Celtic Pharma Announces Presentation of Preclinical Data at the 69Th Annual Meeting of the Aad in New Orleans
Feburary 07, 2011
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”), the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the presentation of key in-vitro data at the American Academy of Dermatology (AAD) 69th annual meeting in New Orleans (4-8 February, 2011) for TDT 067, terbinafine in Transfersomes, for the topical treatment of onychomycosis (also known as a fungal nail infection).
Read the full press release
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
October 21, 2010
Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept® with Avastin®.
Read the full press release
Celtic Pharma announces initiation of phase III trial of TDT 067 for the treatment of Onychomycosis
April 30, 2010
Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma"), the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of Onychomycosis (also known as a fungal nail infection).
Read the full press release
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT® in Pediatric Patients with Primary and Metastatic Brain Tumors
April 21, 2010
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”) today announced the initiation of a Phase I/II pediatric dose tolerance trial to test their investigational new drug XERECEPT® in pediatric patients suffering from primary, recurrent or metastatic brain tumors.
Read the full press release
Celtic Pharma Announces Preclinical Findings that XERECEPT® Potentiates Significantly the Tumor Inhibition Activity of Avastin®
April 19, 2010
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”) today reported at the AACR 101st Annual Meeting 2010 in Washington, DC the results from several preclinical studies of XERECEPT® in established models for breast, colon and brain tumors.
Read the full press release
Celtic Pharma Announces Strategic Partnership Between Ipsen and Inspiration Biopharmaceuticals
January 21, 2010
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”) today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals (“Inspiration”) to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio.
Read the full press release
Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Patients with Primary and Metastatic Brain Tumors
June 1, 2009
Administration of XERECEPT®in Patients with Cerebral Edema Demonstrated Clinically Significant Reductions in Steroid Usage Compared to Placebo.
New Preclinical Studies Indicate XERECEPT®May Have Direct Anti-Tumor and Angiogenesis Inhibition Activity.
Read the full press release
Celtic Pharma Announces Successful Outcome of Phase II Trial for Topical Treatment of Onychomycosis
March 26, 2009
Celtic Pharma announced the successful outcome of its Phase II trial of TDT-067, terbinafine in Transfersomes, for the treatment of onychomycosis.
Read the full press release